Purinergic Signaling During

Immune Cell Trafficking by Ferrari, Davide et al.
Review
Purinergic Signaling During
Immune Cell Trafficking
Davide Ferrari,1,* Eóin N. McNamee,2 Marco Idzko,3
Roberto Gambari,1 and Holger K. Eltzschig2
Migration and positioning of immune cells is fundamental for their differentiation
and recruitment at sites of infection. Besides the fundamental role played by
chemokines and their receptors, recent studies demonstrate that a complex
network of purinergic signaling events plays a key role in these trafficking
events. This process includes the release of nucleotides (such as ATP and
ADP) and subsequent autocrine and paracrine signaling events through nucle-
otide receptors. At the same time, surface-expressed ectoapyrases and nucle-
otidases convert extracellular nucleotides to adenosine, and adenosine
signaling events play additional functional roles in leucocyte trafficking. In this
review we revisit classical paradigms of inflammatory cell trafficking in the
context of recent studies implicating purinergic signaling events in this process.
The Purinergic Network: Transducing Extracellular Nucleotide and
Nucleoside Signaling
Nucleotides such as ATP, UTP, GTP, and ADP and the nucleoside adenosine are well known for
their fundamental intracellular roles. ATP, for example, represents an ‘energy store’ for virtually all
cells and in addition is a basic constituent of nucleic acids and a crucial enzyme modulator.
Interestingly, nucleotides and nucleosides show completely different roles when present in the
extracellular compartment. Hence, liberation of ATP, UTP, UDP, ADP, and adenosine occurs in
many cell types and in completely different contexts [1,2]. Any cell can passively release
nucleotides and nucleosides if the plasma membrane undergoes heavy stress or damage.
The main cell membrane stressors include allergens, extracellular proteases, oxygen radicals
(ROIs), and shear stress forces (Figure 1) and also bacterial products and viruses. It has become
clear that cells physiologically (i.e., in the presence of homeostatic conditions) release, in a
regulated manner, nucleotides and nucleosides that function as extracellular signaling molecules
[1,2]. Regardless of where they come from, once in the extracellular milieu nucleotides and
nucleosides bind specific plasma membrane receptors needed for cell-to-cell communication
named purinergic receptors. These are grouped into P2 and P1 receptors, respectively [3].
Based on their sequence and signaling properties, the G protein-coupled P1 receptors are
further distinguished as four subtypes (A1, A2A, A2B, and A3), while P2 receptors form two groups
comprising the metabotropic G protein-coupled P2Y receptors [4] and the ionotropic P2X
receptors [5]. Nucleotides (ATP, ADP, UTP, and UDP) formed or released in the extracellular
compartment bind and activate P2 receptors, while adenosine present in the extracellular milieu
is an agonist for P1 receptors.
P2Y receptors are seven-transmembrane spanning receptors expressed by virtually all mam-
malian tissues. They have an extracellular NH3 domain, while the COOH terminus is intracellular.
Unlike P2X receptors, they are not ion channels and their activation induces the formation of
various intracellular messengers and liberation of Ca2+ from intracellular stores. Eight P2Y
receptors have been identified so far: P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13,
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and P2Y14 [4]. The first five couple to G/q family proteins and activate phospholipase C-b (PLC-
b) isozymes; the ATP-activated P2Y11 receptor also couples to G/s activating adenylyl cyclase.
P2Y12, P2Y13, and P2Y14 couple to the G/i/o family and inhibit adenylyl cyclase activity. The
abundance of P2Y subtypes is paralleled by the variety of endogenous ligands able to bind them
[4]: ATP, ADP, UTP, UDP, UDP-glucose, and other UDP-sugars as well as uridine adenosine
tetraphosphate (Up4A). While ADP activates the P2Y1, P2Y12, and P2Y13 subtypes, ATP is an
agonist at P2Y2 and P2Y11. Uridine nucleotides (UTP and UDP) activate P2Y2, P2Y4, and
P2Y6. P2Y14 is activated by UDP, UDP-glucose and other UDP-sugars [4]. Involvement of
some P2Y receptor subtypes (P2Y2, P2Y6, and P2Y12) in host defense and inflammation has
been ascertained [6,7].
Receptors for extracellular ATP and ADP are named P2X receptors. These are plasma mem-
brane channels selective for monovalent and divalent cations (Na+, K+, Ca2+, Mg2+) that are
directly activated by the agonist [5]. Seven different subunits have been identified so far and
numbered from 1 to 7 (P2X1R–7R). They have two transmembrane domains, a large extracel-
lular loop with the ability to bind ATP, which is an agonist at all subtypes, and intracellular N and C
termini. Opening of the receptor channel by the agonist induces transmembrane ion fluxes
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Figure 1. The Purinergic Network. A range of events including hypoxia, apoptosis, necrosis, stress due to mechanical
forces, infections by microorganisms, secretion of proteases, and production of oxygen radicals (ROIs) cause cells to
release nucleotides and nucleosides into the extracellular milieu. Once released extracellularly, nucleotides (ATP, ADP, UTP,
UDP, etc.) behave as signaling molecules through activation of the purinergic P2 (P2Y and P2X) receptors. The extracellular
presence of the nucleoside adenosine (ADO) is mainly due to generation at the cell membrane as a consequence of the
enzymatic conversion of ATP to ADO by sequential activation of the ectonucleoside triphosphate diphosphohydrolase
CD39 (ATP/ADP converted to AMP) and the ecto-50-nucleotidase CD73 (AMP converted to adenosine). ADO is an agonist
at P1 purinergic receptors, which are represented by four subtypes: A1, A2A, A2B, and A3.
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leading to plasma membrane depolarization, activation of Ca2+- and K+-dependent enzymatic
cascades as in the case of P2X7-mediated pro-caspase 1 activation, and subsequent pro-IL-1
and pro-IL-18 cleavage and secretion [8,9].
In the case of ATP and ADP, nucleotide metabolism produces adenosine, which activates P1
receptors [10,11]. Four ectonucleotidase groups [i.e. ectonucleoside triphosphate diphos-
phohydrolases (NTPDases), ecto-59-nucleotidase (CD73), ectonucleotide pyrophosphatase/
phosphodiesterase, and alkaline phosphatases] [12] have been identified and have the ability
to degrade ATP and its metabolites, eventually leading to adenosine production [13]. Plasma
membrane receptors for extracellular adenosine are named P1 receptors. The four identified
subtypes (A1, A2A, A2B, and A3) share a common membrane topology, with seven-trans-
membrane spanning domains, and all couple to G proteins [14]; their activation induces
concentration changes in the intracellular second messenger cAMP and, with the A2B
subtype, Ca2+ release from intracellular stores. Adenosinergic receptors modulate many
biological functions, ranging from heart rate, vascular tone, and neuron excitation to the
immune response. Concerning the latter, they mainly activate anti-inflammatory pathways
[15]. Adenosine is then sequestered or degraded extracellularly, thus causing termination of
P1-mediated signaling [16].
Besides ‘stress-induced’ nucleotide release, different cell types (neurons, platelets, endothe-
liocytes, lymphocytes, epithelial cells) can release ATP and ADP through specialized plasma
membrane molecules (connexin hemichannels, pannexin channels, the P2X7 receptor, ABC
transporters, ATP-conducting anion channels) [17,18]. A recently identified system allows
accumulation of ATP in intracellular vesicles expressing the vesicular nucleotide transporter
(VNUT) SLC17A9 and release of the nucleotide by exocytosis [19]. Nucleotides and nucleosides
activate immune cells, helping them to fight microbes [20]. However, uncontrolled ATP release
has been shown to induce excessive secretion of proinflammatory mediators (prostaglandins,
ROIs, chemokines, proinflammatory cytokines) and massive recruitment of immune cells, which
is detrimental for tissue integrity as it exacerbates inflammation [21,22]. To protect tissues,
particularly from immune-mediated tissue damage, adenosine is generated and in many cases
dampens inflammation through P1 receptor stimulation [15]. Therefore, purinergic signaling
represents the result of the activity of a complex and heterogeneous ‘molecular machinery’
comprising nucleotide/nucleoside transporters, plasma membrane P1 and P2 receptors, and
nucleotide-degrading enzymes (CD39, CD73) (Figure 1) cooperating to form the inflammatory
microenvironment in which leukocytes act [12,13]. Accordingly, responses mediated by immune
cells are heavily influenced by, and in many cases dependent on, the purinergic signaling
predominating in a particular tissue context [16]. In particular, P1 and P2 receptors frequently
show opposing effects in terms of modulation of the immune response, and shifting the balance
from purinergic P2-mediated signaling (mostly proinflammatory) to adenosine-mediated P1
signalling (prevalently anti-inflammatory) or vice versa may have important consequences on
the immune outcome. In other words, stimulation of adenosine receptors exerts beneficial
effects by down-modulating inflammation and thus protecting tissues from immune-mediated
damage [15] while activation of P2 receptors by ATP can exacerbate and prolong tissue
inflammation [16].
Recent findings implicate a role for purinergic signaling in producing and modulating the
chemotaxis (see Glossary) of leukocytes, since autocrine and paracrine stimulation of
P1 and P2 receptors substantially contributes to cell polarization and leucocyte migration
[23–26]. Moreover, nucleotides and nucleosides contribute to regulating the secretion of
chemokines, which is fundamental in attracting immune cells to the site of infection [27–30]; in
most cases, P1 receptors inhibit or reduce chemokine secretion while P2 receptor stimula-
tion increases it.
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Chemotactic Properties of Nucleotides and Nucleosides
To respond to an infection, immune cells have to reach tissue sites where invading micro-
organisms are present. Therefore, leukocytes are programmed to exit the circulation and move
toward epicenters of infection/inflammation, guided by chemical gradients of various stimuli. The
oriented migration of cells inside chemical gradients is termed ‘chemotaxis’ and is evoked by so-
called ‘chemoattractants’, a large and heterogeneous group of chemicals including both soluble
molecules produced by the host and non-self constituents [N-formyl peptides, lipopolysaccha-
ride (LPS)] from invading microorganisms [31]. The former include platelet-activating factor
(PAF), complement protein 5a (C5a), leukotriene B4 (LTB4), lipoxin A4 (LXA4), and the large
chemokine family [31,32].
The chemotactic process involves a complex sequence of coordinated changes that are made
possible by the expression on the cell membrane of chemotaxis receptors that, on binding with
their ligands, allow cells to proceed in a chemical gradient. Convincing data obtained by
pharmacological inhibition of various purinergic subtypes or by knockout mice for single P1
or P2 receptor subtypes clearly show that nucleotides and nucleosides function as chemo-
attractants for leucocytes, particularly phagocytes; an example is the reduction of chemotaxis in
monocytes/macrophages in the presence of the enzyme apyrase (which degrades extracellular
ATP) and in animals lacking the P2Y receptor subtype (P2Y2/ mice). Moreover, pharmaco-
logical inhibition or stimulation of single or multiple purinergic receptor subtypes has also been
important in understanding extracellular nucleotide- and nucleoside-induced chemotaxis
[22,33,34]. Another interesting finding is that purinergic receptors contribute to both positive
excitatory signals (needed at the front of the cell) and the inhibitory signals that must be provided
to the rest of the plasma membrane, particularly to the back of a migrating cell to allow its
navigation in a chemotactic gradient [35]. Therefore, the concerted participation ATP/ADP-
activated P2 receptors, ectonucleotidases (to generate adenosine), and P1 receptors is needed
to obtain efficient chemotactic migration.
Initial studies documented the chemotactic effects of pharmacologically added nucleotides
(ATP, ADP, UTP, UDP-glucose in immune cells) [24,26,36,37], but it was also realized that
chemotactic stimuli released by microorganisms (fMLP, LPS) or formed during the onset of
inflammation (C5a) evoke the release of nucleotides that enhance or cooperate in the production
of robust cytokine secretion and efficient chemotactic migration, thus increasing the likelihood
that invading microorganisms will be reached and eliminated [23]. The contribution of autocrine
purinergic signaling to leukocyte migration is not ancillary since, for example, enzymatic degra-
dation of secreted ATP by apyrase impairs monocyte migration and recruitment in a mouse
model of C5a-induced peritonitis [38].
Besides defense against invading microorganisms, phagocytes have the fundamental role of
eliminating dead cells and tissue debris. Although it is intuitive that damaged tissues or necrotic
cells release ATP, it is less intuitive that apoptotic cells also release nucleotides that function as
a ‘find-me signal’ inducing oriented migration of phagocytes and thus favoring apoptotic body
clearance [23,39,40]. To this purpose, the participation of pannexin-1 channels links ATP release
to chemotaxis. Interestingly, in neutrophils the Pannexin-1 channel (PANX-1) determines the
release of ATP and autocrine stimulation of the cell via P2Y2 and A3 receptors [41]. Besides
neutrophils, involvement of the P2Y2 receptor in chemotaxis has been demonstrated in eosin-
ophils, macrophages, microglia, and dendritic cells (DCs) [24,40,42–44]. Damaged neurons
release UDP, which stimulates P2Y6-dependent chemotaxis of microglial cells; however, micro-
glial cells lacking the P2Y12 subtype lose the capacity to polarize their plasma membrane, extend
pseudopodia, and migrate towards brain-damaged areas in mice, suggesting that participation
of this subtype is required in the ‘preparatory’ steps of chemotaxis [45]. Intriguingly, nucleotides
are involved in chemotaxis stimulated by other chemoattractants, such as in the case of the
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complement protein C5a. It has been elegantly shown that macrophages migrating in a C5a
gradient release ATP that activates P2Y2 and P2Y12 receptors and, once degraded by ectonu-
cleotidases, produces adenosine that stimulates P1 receptors in an autocrine manner [40].
Involvement of P1 receptors in chemotaxis of leukocytes has been shown in neutrophils, microglia,
and eosinophils; however, the role of some P1 receptors (for example, the A3 subtype) in
chemotaxis remains controversial. While the A1 receptor promotes neutrophil chemotaxis [46]
the A2A and A3 subtypes would inhibit it, and the A2B receptor would be inhibitory for microglial
chemotaxis [25,47–49]. Therefore, secretion of ATP and its hydrolysis to ADP, AMP, and adeno-
sine are critical steps in the modulation of leukocyte chemotaxis.
What Is the Link between Chemokines and Purinergic Signaling?
Recent studies have highlighted the link between purinergic signaling and chemotactic path-
ways activated during the immune response, and compelling evidence shows that nucleotides
and nucleosides are endowed with the ability to modulate chemokine secretion [50–53]. Cell
chemotaxis is preceded by membrane polarization and important morphological changes
paralleled by redistribution of intracellular signal transduction proteins implicated in motility,
directional sensing, and polarity. These events include accumulation of the intracellular second
messenger phosphatidylinositol 3,4,5-trisphosphate (PIP3), Rac-mediated actin polymerization,
Rho and calcium modulation of actin- and myosin-mediated cell contraction, and redistribution
of phosphatase and tensin homolog (PTEN) and myosin II [54]. Triggering of chemokine
receptors by their ligands induces formation of intracellular phospholipids and calcium concen-
tration increases [55]. Extracellular nucleotides seem to substantially contribute to chemokine
receptor signaling by increasing the amplitude of the total calcium increase. Elegant experiments
performed by heterologous expression of chemokine receptors in CHO cells indicate the need
for P2Y-mediated pre-stimulation with ATP to induce CCR4-dependent Ca2+ concentration
increase [56]. Accordingly, Ca2+ signaling induced by the binding of the chemokine CXCL8 to
the recombinant CXCR2 chemokine receptor is potentiated by pre-stimulation of cells with ATP
or UTP and putative involvement of the P2Y1 and P2Y2 subtypes has been hypothesized [57].
Interestingly, a recent report showed that the monocytic cell line THP-1 rapidly secretes ATP on
activation of the monocyte chemotactic protein 1 (MCP-1)–MCP1R axis and the authors
suggest that P2Y6, which is not activated by ATP, might act as a coactivator of cell chemotaxis
stimulated by CCL2 since P2Y6 activation is responsible for 80% of the intracellular Ca2+ signal
evoked by CCL2 in these cells [52]. Also peculiar is the fact that the same nucleotide has
opposite effects on chemotaxis induced by two different cytokines. Thus, ATP inhibits natural
killer (NK) cell chemotaxis in response to CX3CL1 while it increases that stimulated by CXCL12
[58]. In other cases nucleotides inhibit chemokine secretion; as an example, in human mast cells
ADP and ATP block CXCL8 and CCL4 secretion in response to leukotriene D4 [59]. These
findings indicate that nucleotides and nucleosides not only are chemoattractants per se [60–62],
but: (i) induce/inhibit chemokine secretion; and (ii) modulate production of chemokines stimu-
lated by proinflammatory mediators. In the following sections, we describe the role of extracel-
lular nucleotides and nucleosides in modulating chemokine secretion and chemokine-mediated
immune responses, highlighting the fact that P2 receptor stimulation promotes inflammatory
responses by upregulating expression of various chemokine genes and inducing chemokine
secretion. This may in some cases exacerbate inflammation, thus causing tissue damage. By
contrast, P1 receptor activation in most cases inhibits chemokine secretion and reduces
phagocyte recruitment, thus protecting tissues from immune-mediated cell damage.
P1 Receptors and Chemokines
Adenosine and its receptors play a fundamental role in the immune response mainly by down-
modulating multiple cytokine expression and secretion [17]. Recent data have confirmed the role
of adenosine in modulating chemokine secretion and chemokine receptor activation and a deep
investigation has been undertaken to shed light on the complex interplay between adenosine
Trends in Immunology, June 2016, Vol. 37, No. 6 403
and chemokines in tuning leukocyte functions [63–67] (Figure 2A). Most of these studies indicate
that adenosine through its receptors decreases chemokine production and dampens inflam-
mation thus reducing tissue damage (Table 1). Hypoxic conditions induce adenosine formation
in the extracellular milieu [10] and adenosinergic receptors are involved in hypoxia-related
signaling pathways [68]. In particular, the A2A subtype is involved not only in T cell apoptosis
but also in the signaling pathway that reduces CCR7 expression under hypoxic conditions [69].
The same subtype participates in the downregulation of CXCR4 and CCR5 induced by an
agonist-like monoclonal antibody [64]. A crucial aspect related to the establishment of hypoxic
conditions is lack of infiltration of tumor mass by cytotoxic T lymphocytes. This is mainly due to
stimulation by adenosine of the A2A subtype [70]. The authors demonstrated that hypoxic
conditions present in the tumor microenvironment (TME) were able to modify the cytokine and
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Figure 2. Purinergic Signaling and Chemokines. Involvement of specific P1 (A) and P2 (B) receptors in modulation of chemokine secretion. (A) Adenosine (ADO)
reduces or inhibits secretion of various chemokines by immune cells. The A2A subtype blocks CXCL10 production by microglia, CCL3, CCL4, CXCL2, and CCL20 by
neutrophils, and CCL2, CCL3, CCL4, CCL5, CXCL9, and CXCL10 by macrophages stimulated with bacterial endotoxin (LPS). (B) ATP, UTP, and ADP stimulate
chemokine secretion by activating different P2 subtypes. Microglia secrete CCL3 and CXCL2 on stimulation of the P2X7 subtype and CCL2 and CXCL1 as a
consequence of P2Y12 triggering. Activation of the P2Y11 receptor induces CXCL8 secretion by dendritic cells, while the P2Y2 subtype is involved in CCL2 secretion by
macrophages.
404 Trends in Immunology, June 2016, Vol. 37, No. 6
chemokine repertoire towards immunosuppressive responses while elimination of adenosine
and tissue reoxygenation reverted the antitumor immune response [71]. Adenosine has been
implicated in regulating polymorphonuclear (PMN) cell transepithelial migration mediated by
CXCR2 [65]. A2A activation is involved in modulating the chemokine repertoire in human
neutrophils by preventing the expression and release of MIP family molecules (MIP-1//
CCL3, MIP-1ba/CCL4, MIP-2//CXCL2, and MIP-3//CCL20), thus greatly reducing the
responses mediated by these factors (i.e., chemotaxis, degranulation, phagocytosis, and
production of inflammatory mediators that contribute to the onset and progression of
inflammation) [27]. Stimulation of the A3 receptor suppresses the production of CCL3 and
exerts anti-inflammatory effects by decreasing neutrophil recruitment [72]; by contrast, adeno-
sine increases CXCL8 secretion in monocytes/macrophages stimulated by IL-1b [73]. More-
over, the A2B subtype evokes CXCL8 release in an ERK and p38 MAPK-dependent manner in
human mast cells [74–76]. A recent report shows that the A2A receptor inhibits LPS-induced
Table 1. Nucleotides and Nucleosides Modulate Chemokine Secretion and Chemokine Receptor
Expression.
Receptor Agonist Effect on Chemokine/Chemokine Receptor Species Tissue Refs
A2A ADO + Ab CXCR4 # H T cells [64]
CCR5 #
20,30-cAMP CXCL10 # M Microglia [67]
30-AMP
20-AMP
CCR7 # H T cells [69]
CCL3 # M Neutrophils [27]
CCL4 #
CXCL2 #
CCL20 #
CCL2 # H Macrophages [77]
CCL3 #
CCL4 #
CGS 21680 CCL5 # H Macrophages [66]
CXCL9 #
CXCL10 #
CCR7 #
A2B ADO CCL-3 # M Mast cells [76]
A3 IB-MECA CCL3 # M Macrophages [72]
P2X7 ATP CCL3 " M Microglia [50,85]
CXCL2 "
BzATP CCL2 " M Microglia [29]
P2Y2 ATP CXCL8 " H Uroepithelial cells [91]
ATP/UTP CCL2 " R Macrophages [92]
P2Y6 UDP CXCL8 " H Monocytes [88,89]
P2Y11 NF546 CXCL8 " H DCs [93]
P2Y12 CCL2 " M Microglia [53]
CXCL1 "
ADO, adenosine; Ab, antibody; H, human; M, mouse, R, rat.
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production of CCL2, CCL3, CCL4, CCL5, CXCL9, and CXCL10 but not that of CXCL1, CXCL8,
and CXCL5 in human lung macrophages [77] (Figure 1A). Monocytes migrate into tissues in
response to various stimuli among which CCR7, and its chemoattractant agonist CCL21, plays
a central role during the onset of inflammatory conditions underlying atherosclerosis. Interest-
ingly, activation of the A2A subtype modulates CCR7 expression under both normal and
inflammatory conditions and tunes macrophage migration in response to CCR7-specific che-
moattractants [66] (Table 1).
The role of chemokines in directing and activating immune cells has also been shown in the nervous
system. The recent finding that mouse microglia possesses the extracellular 2’,3’-cAMP–adeno-
sine pathway converting released 2’,3’-cAMP to adenosine prompted an investigation into the role
of adenosine in modulating chemokine release by microglia; in particular, A2A receptor stimulation
exerts an inhibitory effect on CXCL10 production by activated primary murine microglia [67]
(Figure 1A). A role for adenosine in driving migration of lymphocytes has also been described
in the central nervous system. Hence, the nucleoside induces expression of CX3CL1 at the choroid
plexus during experimental autoimmune encephalomyelitis (EAE) through immunization with
myelin oligodendrocyte glycoprotein (MOG 35–55). It has been demonstrated that mice lacking
expression of CD73 and consequently unable to produce extracellular adenosine do not upreg-
ulate CX3CL1 and do not show brain lymphocyte infiltration [78]. Moreover, the A2A receptor
subtype has been implicated as a mediator of this lymphocyte function, as inhibition of the subtype
by the specific antagonist SCH58261 protects wild-type (WT) mice from EAE, which represents an
experimental model for multiple sclerosis [79]. Another interesting finding is that the fractalkine–
CX3CR1 signaling pathway plays a role in modulating microglial activation and neuron survival [80]
and it is relevant that CX3CL1 is able to rescue neurons from neuronal excitotoxic death only in the
presence of functional A1 receptor, as confirmed by the fact that hippocampal neurons from A1
receptor/ mice are not rescued from Glu-induced cell death [81]. Therefore, modulation of
adenosine receptors may be a strategy worthy of further evaluation for acute and chronic
inflammatory disorders in the nervous and other systems.
P2X Receptors and Chemokines
Activation of the P2X1 receptor by ATP promotes neutrophil chemotaxis, a process involving
Rho kinase-dependent actomyosin-mediated contraction at the cell rear [62]. Due to the
massive recruitment of leukocytes, excessive chemokine secretion can be deleterious for tissue
integrity [16,82]. P2 purinergic signaling is actively involved in the potentiation of chemokine
secretion induced by leukocyte peptides such as the human neutrophil antimicrobial peptides,
thus increasing expression of CXCL8 in the colonic mucosa of patients with active ulcerative
colitis [30]. P2-mediated amplification of chemokine secretion also occurs in the case of bacterial
toxin induction of CXCL8 secretion, which is the basis of intestinal epithelial barrier dysfunction
[28]. The same is true for CCL2, which massively recruits monocytes in chronic inflammatory
diseases and whose secretion consistently contributes to the inflammatory background of
psoriasis, uveitis, multiple sclerosis, asthma, and chronic obstructive pulmonary disease [83]. A
potentially interesting finding for new therapeutic approaches based on the modulation of
chemokine secretion by purinergic signaling is the observation that the epidermis of psoriatic
patients shows increased expression of P2X7 at the cell membrane of the basal layer [84].
Moreover, stimulation by ATP of IFN-g-treated human keratinocytes induces a complex modu-
lation of chemokine secretion with increased production of CCL2, CCL5, and CXCL8 and
downregulation of CXCR3, CXCL9, CXCL10, and CXCL11 [84] (Figure 2B). P2X receptors have
been shown to participate in human and mouse neutrophil chemotaxis induced by bacterial
products such as formylated peptides or CXCL8 both in vitro and in vivo.
Microglia have the potential for both positive and negative effects in the central nervous system.
Among signals able to ‘overactivate’ microglial cells and promote neurotoxicity, ATP has the
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capacity to stimulate the release of inflammatory cytokines (IL-6, IL-1b, TNF-/) and chemokines
[29,85]. Stimulation of the P2X7 receptor subtype by ATP or 20(30)-O-(4-benzoylbenzoyl)-ATP
(BzATP) induces mRNA expression and release of the chemokine CCL2 in WT mouse microglia
but not in P2X7/ cells, showing that this subtype, and not other P2X receptors, is responsible
for nucleotide-induced CCL2 production by microglial cells [29]. It has been shown that
extracellular ATP induces activation of the transcription factor nuclear factor of activated
T cells (NFAT) in mouse microglial cells and recent data indicate a role of NFAT in P2X7-induced
CCL3 and CXCL2 secretion in microglia [50,85] (Figure 2B and Table 1). Peculiarly, stimulation
of cells with chemokines also modulates nucleotide-mediated effects. Hence, pretreatment of
microglial cells with CX3CL1 significantly inhibits ATP-induced apoptosis in microglia and
transforms, in a PI3-kinase-dependent manner, amoeboid microglia into quiescent, ramified
forms [86]. Therefore, much effort is required to study the reciprocal effects of purines and
chemokines with the aim of managing the undesirable effects caused by these systems.
P2Y Receptors and Chemokines
The involvement of Gi protein-coupled receptors, including P2Y receptors, in modulating
chemokine secretion by immune cells emerged some years ago. This finding was supported
by the observation that UDP stimulated the release of CXCL8 from LPS-matured human
monocyte-derived dendritic cells, which are professional antigen-presenting cells obtained
by in vitro differentiation of peripheral human monocytes in the presence of GM-CSF and IL-
4 followed by maturation in the presence of bacterial endotoxin (LPS) [87]. LPS induces the
release of ATP and UDP in monocytic cells thus promoting CXCL8 secretion in a P2Y6-mediated
manner [88,89]. A requirement for this subtype for CXCL8 secretion has also been shown in
nonimmune cells, as stimulation of lung epithelial cells with ATP or UDP induces CXCL8
secretion and inhibition of P2Y6 blocks it thus preventing recruitment of inflammatory cells
(monocytes, neutrophils, etc.) to the lung parenchyma [90] (Table 1).
Bacterial toxins induce the release of chemokines attracting immune cells. Clostridium difficile
toxins A and B, for example, trigger the release of CXCL8 from intestinal epithelial cells, attracting
neutrophils that contribute to disruption of the intestinal epithelium. Intoxication of human
epithelial colorectal adenocarcinoma (Caco-2) cells induces UDP release, P2Y6 activation,
and increased CXCL8 expression [28]. Data obtained in mice with colitis-like disease indicate
a role of the P2Y6 receptor in neutrophil recruitment to inflamed intestinal mucosa; the process is
mainly due to increased CXCL8 expression evoking massive neutrophil recruitment [28].
Interestingly, enemas with the P2Y6 agonist UDP increase CXCL8 expression in mice and
mutations at the AP-1 consensus site completely block the UDP-mediated effect [51]. Although
P2Y6 is clearly involved in CXCL8 secretion, this subtype seems to be not essential for secretion
of the cytokine in all systems. For example, neutrophil peptides induce secretion of the
chemokine in the HT-29 cell line, which does not express the P2Y6 subtype [7,30]. The
P2Y2 subtype is likely to be another candidate for purinergic-mediated CXCL8 secretion since
stimulation of uroepithelial cells by ATP induces P2Y2-mediated release of CXCL8 [91]. More-
over, in rat peritoneal and alveolar macrophages (NR8383 cell line), constitutive CCL2 release is
increased by ATP or UTP via the P2Y2 subtype [92]. While extracellular ATP protects endothelial
cell from CX3CL1-stimulated NK killing activity in a P2Y11-dependent manner [58], the same
subtype stimulates CXCL8 secretion by Ds [93]. The P2Y12 subtype has recently been shown to
modulate CCL2 and CXCL1 release by mouse microglia in brain tissue slices and blockade
of this subtype inhibits CCL2 and CXCL1 secretion [53]. Different chemokines are involved in the
pathological recruitment of lymphoid cells, a characteristic feature of several chronic inflamma-
tory diseases. Among them, CCL2 plays a role in recruitment of monocytes in psoriasis,
rheumatoid arthritis, and atherosclerosis [94]. Due to the fact that different P2Y subtypes
(P2Y2, P2Y6, P2Y12) stimulate the secretion of chemokines involved in pathological states,
clarification of the interplay between purinergic P2Y-mediated signaling and chemokine
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secretion would contribute to improving our knowledge of the pathogenesis and progression of
these diseases and is likely reveal novel therapeutic targets.
Ectonucleotidases and Chemokines
Nucleotide-metabolizing enzymes play a role in controlling the concentration of nucleotides
available for P1 and P2 receptor activation [12,13]. In particular, their activity decreases ATP
and ADP concentrations, thus dampening P2 receptor-mediated responses, while increasing
adenosine concentration and, consequently, ‘protective’ P1-induced effects. Recent data
indicate a role for these enzymes in modulating the secretion of various chemokines, and
pharmacological inhibition or lack of expression of these enzymes has the net effect of
increasing chemokine production. Human neutrophils express NTPDase1 (CD39) and inhibi-
tion of this enzyme greatly increases CXCL8 secretion in TLR-stimulated human neutrophils.
Accordingly, injection of LPS in the air pouches of NTPDase1-deficient mice leads to increased
secretion of the rodent counterparts of human CXCL8, the chemokine CXCL2 and keratino-
cyte-derived chemokine [95]. Another recent report showed that degradation of extracellular
nucleotides with apyrase greatly decreases THP-1 sensitivity to CCL2, while inhibition of CD39-
like ectonucleotidases potentiates CCL2-induced Ca2+ responses [52]. Although further
investigation is needed to confirm and integrate initial observations on the interplay between
ectonucleotidase activity and chemokine secretion, we can hypothesize that ectonucleoti-
dases have the ability to dampen inflammation by increasing adenosine concentration in the
extracellular compartment and consequently decreasing chemokine production and excessive
immune cell recruitment.
Concluding Remarks and Future Perspectives
Exaggerated inflammatory response is the basis of the pathogenesis of various diseases such as
psoriasis, rheumatoid arthritis, atherosclerosis, inflammatory bowel disease, asthma, and multi-
ple sclerosis [96,97]. Therefore, it is urgent to identify mechanisms and pathways underlying
pathologic inflammatory states to reveal new therapeutic targets and novel treatments
(see Outstanding Questions). Although chemokines are needed to mount an adequate defen-
sive response, excessive chemokine secretion induces abnormally high leukocyte recruitment
paralleled by increased release of toxic mediators with consequent tissue damage. Dysregu-
lation of chemokine expression causes excessive recruitment of leukocytes [98,99]. Various
attempts are ongoing to therapeutically target chemokines by specific inhibitors and to find novel
anti-inflammatory and proresolutive molecules [83]. Purinergic signaling has been the focus of
increasing attention with the aim of dampening P2 proinflammatory and amplifying P1 anti-
inflammatory responses [99,100]. Since P1 receptors down-modulate and P2 receptors up-
modulate chemokine expression and secretion, in future trials it will be important to pay more
attention to the interplay between purinergic signaling and chemokines to reduce/control the
negative effects of excessive chemokine production in diseases in which abnormal recruitment
of immune cells and subsequent repeated induced tissue damage are critical pathogenic
factors, such as autoimmune and chronic inflammatory diseases.
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